tHEORetically Speaking – Détails, épisodes et analyse

Détails du podcast

Informations techniques et générales issues du flux RSS du podcast.

tHEORetically Speaking

HealthEconomics.com

Sciences

Fréquence : 1 épisode/20j. Total Éps: 87

Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/

Lire plusRéduire

Site

RSS

Apple

Données mises à jour le 03/08/2026

Classements récents

Dernières positions dans les classements Apple Podcasts et Spotify.

Apple Podcasts

Spotify

Aucun classement récent disponible

Liens partagés entre épisodes et podcasts

Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.

https://www.trialinsights.com/
9 partages
https://healtheconomics.com/podcast/between-two-scientists-labeling-and-certifying-your-varietal-data-blend/
2 partages
https://healtheconomics.com/newsletter-contact-form/
2 partages

https://www.linkedin.com/company/healtheconomics-com/
4 partages

Qualité et score du flux RSS

Évaluation technique de la qualité et de la structure du flux RSS.

Qualité du flux RSS

À améliorer

Score global : 63%

Historique des publications

Répartition mensuelle des publications d'épisodes au fil des années.

Year

Derniers épisodes publiés

Liste des épisodes récents, avec titres, durées et descriptions.

Weekly News Roundup – Real-World Wins and Billion-Dollar Breakthroughs

Saison 4 · Épisode 22

vendredi 24 octobre 2025 • Durée 03:50

This week’s tHEORetically Speaking News Roundup covers Astellas Pharma’s Phase 4 findings showing fezolinetant’s real-world benefits for menopausal symptom relief, improved sleep, and daily functioning. We also dive into Takeda’s $11 billion collaboration with Innovent Biologics to advance next-generation cancer therapies and expand its global oncology pipeline.

Tune in for this concise recap of these pivotal industry updates!

Lire plusRéduire

INsights & OUTcomes with Dalfoni Banerjee

Saison 4 · Épisode 21

mardi 21 octobre 2025 • Durée 19:08

This episode features Dalfoni Banerjee, an award-winning entrepreneur and consultant with over 30 years of hands-on experience and her expertise spans the full drug development cycle.

In 2011, Dalfoni founded and continues to operate 3Sixty Pharma Solutions, which has a mission to support startup and established pharmaceutical, biotechnology, and medical device companies with subject matter experts who help teams accelerate development, overcome challenges, and avoid preventable delays.

Learn more about 3Sixty Pharma Solutions here: https://3sixtypharma.com/

Introducing Trial Insights—the essential tool for pharma researchers and biotech investors.

Seamlessly track clinical trials in real-time, refine searches by key criteria, and receive timely notifications on important updates. With Trial Insights, ensure your research and business initiatives are always informed and strategically positioned for success.

Start exploring thousands of trials today at trialinsights.com

Lire plusRéduire

Weekly News Roundup – CAR-T Safety Alerts, Policy Ripple Effects, and Notable Wearables

Saison 4 · Épisode 20

vendredi 17 octobre 2025 • Durée 03:50

This week’s tHEORetically Speaking News Roundup covers the FDA’s new boxed warning for J&J’s CAR-T therapy Carvykti, a major study linking post-Dobbs abortion restrictions to rising intimate partner violence, and Pelage Pharmaceuticals’ $120M funding to advance a next-generation hair loss treatment. We also spotlight Ōura’s $900M investment to expand its AI-driven health tech platform.

Tune in for this concise recap of these pivotal industry updates!

Lire plusRéduire

Weekly News Roundup – Immunology, Innovation, and Impact

Saison 4 · Épisode 19

vendredi 10 octobre 2025 • Durée 03:59

This week’s tHEORetically Speaking News Roundup covers nirsevimab’s real-world success in reducing RSV hospitalizations among infants, Boehringer Ingelheim’s FDA approval of Jascayd for idiopathic pulmonary fibrosis, and Arthrosi Therapeutics’ $153 million raise to advance a next-generation gout drug. We also highlight this year’s Nobel Prize in Medicine, honoring discoveries in immune tolerance that continue to shape today’s biggest breakthroughs.

Tune in for this concise recap of these pivotal industry updates!

Lire plusRéduire

tHEORetically Speaking: Rethinking Decentralization in Direct-to-Patient Studies

Saison 4 · Épisode 18

lundi 6 octobre 2025 • Durée 15:05

In this episode of tHEORetically Speaking, Paige McGarry interviews Aaron Berger, SVP & Head of Evidence Development Solutions at UBC discussing the evolution of direct-to-patient (DTP) study designs and how they are reshaping the landscape of clinical research.

Learn more here: https://healtheconomics.com/theoretically-speaking-rethinking-decentralization-in-direct-to-patient-studies/

Introducing Trial Insights—the essential tool for pharma researchers and biotech investors.

Start exploring thousands of trials today at trialinsights.com

Lire plusRéduire

Weekly News Roundup – Medicaid Deals, Oncology Innovation, and Market Tensions Abroad

Saison 4 · Épisode 17

vendredi 3 octobre 2025 • Durée 03:16

This week’s tHEORetically Speaking News Roundup covers Pfizer’s new Medicaid pricing deal with the current administration, Cartography Biosciences’ $67M raise to advance its next-generation colorectal cancer therapy, and calls for a U.K. anticompetition probe into pharma investment freezes.

Tune in for this concise recap of the key HEOR, RWE, and Market Access headlines shaping our industry.

Lire plusRéduire

INsights & OUTcomes with Renée Arnold

Saison 4 · Épisode 16

mardi 30 septembre 2025 • Durée 27:09

This episode features Dr. Renée Arnold, the President & CEO of Arnold Consultancy & Technology, LLC (ACT), focusing on outcomes research and software for healthcare sectors. She specializes in evidence-based health and real-world data modeling for healthcare decisions.

Dr. Arnold is a founding member of ISPOR and chairs a special interest group at the Society for Medical Decision Making, with numerous publications in her field.

Learn more about some of Renée's work here: https://healtheconomics.com/modex-revolutionizing-cancer-drug-pricing-and-access-through-open-source-health-economic-models/

Introducing Trial Insights—the essential tool for pharma researchers and biotech investors.

Start exploring thousands of trials today at trialinsights.com

Lire plusRéduire

Weekly News Roundup – Public Health Flashpoints, Pharma Innovation, and Pricing Battles

Saison 4 · Épisode 15

vendredi 26 septembre 2025 • Durée 05:02

This week’s tHEORetically Speaking News Roundup covers the ACIP’s heated vaccine policy debates, growing state-level divides in COVID-19 vaccine access, and pharma’s race to develop multi-specific antibodies. We also explore the looming $32 billion revenue loss tied to expiring ACA subsidies and the latest legal battles over IRA drug pricing.

Tune in for this concise recap of these pivotal industry updates!

Lire plusRéduire

Weekly News Roundup – Vaccine Policy Shifts, AI-Powered R&D, and Billion-Dollar Investments

Saison 4 · Épisode 14

vendredi 19 septembre 2025 • Durée 04:18

This week’s tHEORetically Speaking News Roundup covers the CDC’s ACIP meeting and its implications for U.S. vaccine policy, GHO Capital’s acquisition of AI-powered R&D platform Scientist.com, and GSK’s $30 billion investment in U.S. drug manufacturing. We also explore Eli Lilly’s promising pediatric trial results for Mounjaro in type 2 diabetes and several upcoming FDA decisions poised to reshape the pharmaceutical landscape.

Tune in for this concise recap of these pivotal industry updates!

Lire plusRéduire

Weekly News Roundup – Pharma Acquisitions, Trial Triumphs, and Coding Controversies

Saison 4 · Épisode 13

vendredi 12 septembre 2025 • Durée 04:35

This week’s tHEORetically Speaking News Roundup covers new research on social-genetic influences in adolescent depression, Novartis’s $1.4B acquisition of Tourmaline Bio for a promising heart drug, and encouraging Phase 2 results for rezatapopt in solid tumors. We also explore the FDA’s draft guidance on non-opioid pain treatments and the AMA’s release of 2026 CPT codes amid growing scrutiny.

Tune in for this concise recap of these pivotal industry updates!

Lire plusRéduire

Podcasts et contenus similaires

Autres podcasts ou contenus associés partageant des thèmes ou audiences similaires.

Podcasts Similaires Basées sur le Contenu

Découvrez des podcasts liées à tHEORetically Speaking. Explorez des podcasts avec des thèmes, sujets, et formats similaires. Ces similarités sont calculées grâce à des données tangibles, pas d'extrapolations !

À propos Méthodologie Contact Me soutenir Politique de confidentialité Mentions légales

tHEORetically Speaking – Détails, épisodes et analyse

Détails du podcast

Classements récents

Apple Podcasts

Spotify

Liens partagés entre épisodes et podcasts

Other92

LinkedIn1

Qualité et score du flux RSS

Historique des publications

Derniers épisodes publiés

Podcasts et contenus similaires

Podcasts Similaires Basées sur le Contenu

Podcasts Similaires Basées sur le Contenu

Other92

LinkedIn1

Apple Podcasts

Spotify